Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma: Single-center experience of 18 years

P. Remenyi, G. Varga, G. Mikala, M. Reti, L. Gopcsa, A. Batai, Z. Csukly, L. Lengyel, E. Torbagyi, A. Barta, J. Fabian, D. Levai, G. Szombath, H. Andrikovics, T. Masszi

Research output: Article

5 Citations (Scopus)

Abstract

Background Autologous stem cell transplantation (ASCT) has become the mainstay of 1st-line treatment in younger patients with multiple myeloma (MM), but statistical confirmation of its superiority over other therapies, especially in the era of novel agents, is still lacking. Methods We reviewed the results of all 548 myeloma ASCTs performed in our institute over the past 18 years. Results More than one-half of the patients had access to novel agents before their transplantations. Although the age of the transplanted patients increased significantly over the years, treatment-related mortality (TRM) was remarkably low, especially in 1st-line transplanted patients (100-day TRM, 0.3%). The median overall survival (OS) of the entire cohort was 98.4 months. Patients transplanted within 12 months from the start of their therapy had significantly better responses than those having delayed ASCT (complete response rate, 58.1% vs 46.8%; P =.016) and significant post-ASCT progression-free survival (PFS) benefit (30.2 [26.1-34.3] mo vs 23.3 [16.8-29.8] mo; P =.036), but we found no significant overall survival difference. The results were similar in patients treated with or without novel agents before ASCT. During a period of time, interferon maintenance was our standard approach to post-ASCT maintenance. Our analysis showed not only a significant PFS advantage with interferon, but also a highly significant overall survival benefit (150.4 [105.1-195.8] mo vs 86.1 [72.5-99.7] mo; P =.003). Conclusions Our findings demonstrate that delayed ASCT can be feasible in selected patients.

Original languageEnglish
Pages (from-to)177-184
Number of pages8
JournalTransplantation Proceedings
Volume48
Issue number1
DOIs
Publication statusPublished - jan. 1 2016

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Interferons
Maintenance
Disease-Free Survival
Survival
Therapeutics
Mortality
Transplantation

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma : Single-center experience of 18 years. / Remenyi, P.; Varga, G.; Mikala, G.; Reti, M.; Gopcsa, L.; Batai, A.; Csukly, Z.; Lengyel, L.; Torbagyi, E.; Barta, A.; Fabian, J.; Levai, D.; Szombath, G.; Andrikovics, H.; Masszi, T.

In: Transplantation Proceedings, Vol. 48, No. 1, 01.01.2016, p. 177-184.

Research output: Article

Remenyi, P, Varga, G, Mikala, G, Reti, M, Gopcsa, L, Batai, A, Csukly, Z, Lengyel, L, Torbagyi, E, Barta, A, Fabian, J, Levai, D, Szombath, G, Andrikovics, H & Masszi, T 2016, 'Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma: Single-center experience of 18 years', Transplantation Proceedings, vol. 48, no. 1, pp. 177-184. https://doi.org/10.1016/j.transproceed.2015.12.031
Remenyi, P. ; Varga, G. ; Mikala, G. ; Reti, M. ; Gopcsa, L. ; Batai, A. ; Csukly, Z. ; Lengyel, L. ; Torbagyi, E. ; Barta, A. ; Fabian, J. ; Levai, D. ; Szombath, G. ; Andrikovics, H. ; Masszi, T. / Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma : Single-center experience of 18 years. In: Transplantation Proceedings. 2016 ; Vol. 48, No. 1. pp. 177-184.
@article{c032e572526e4db5a8686a5f84abe737,
title = "Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma: Single-center experience of 18 years",
abstract = "Background Autologous stem cell transplantation (ASCT) has become the mainstay of 1st-line treatment in younger patients with multiple myeloma (MM), but statistical confirmation of its superiority over other therapies, especially in the era of novel agents, is still lacking. Methods We reviewed the results of all 548 myeloma ASCTs performed in our institute over the past 18 years. Results More than one-half of the patients had access to novel agents before their transplantations. Although the age of the transplanted patients increased significantly over the years, treatment-related mortality (TRM) was remarkably low, especially in 1st-line transplanted patients (100-day TRM, 0.3{\%}). The median overall survival (OS) of the entire cohort was 98.4 months. Patients transplanted within 12 months from the start of their therapy had significantly better responses than those having delayed ASCT (complete response rate, 58.1{\%} vs 46.8{\%}; P =.016) and significant post-ASCT progression-free survival (PFS) benefit (30.2 [26.1-34.3] mo vs 23.3 [16.8-29.8] mo; P =.036), but we found no significant overall survival difference. The results were similar in patients treated with or without novel agents before ASCT. During a period of time, interferon maintenance was our standard approach to post-ASCT maintenance. Our analysis showed not only a significant PFS advantage with interferon, but also a highly significant overall survival benefit (150.4 [105.1-195.8] mo vs 86.1 [72.5-99.7] mo; P =.003). Conclusions Our findings demonstrate that delayed ASCT can be feasible in selected patients.",
author = "P. Remenyi and G. Varga and G. Mikala and M. Reti and L. Gopcsa and A. Batai and Z. Csukly and L. Lengyel and E. Torbagyi and A. Barta and J. Fabian and D. Levai and G. Szombath and H. Andrikovics and T. Masszi",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.transproceed.2015.12.031",
language = "English",
volume = "48",
pages = "177--184",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma

T2 - Single-center experience of 18 years

AU - Remenyi, P.

AU - Varga, G.

AU - Mikala, G.

AU - Reti, M.

AU - Gopcsa, L.

AU - Batai, A.

AU - Csukly, Z.

AU - Lengyel, L.

AU - Torbagyi, E.

AU - Barta, A.

AU - Fabian, J.

AU - Levai, D.

AU - Szombath, G.

AU - Andrikovics, H.

AU - Masszi, T.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background Autologous stem cell transplantation (ASCT) has become the mainstay of 1st-line treatment in younger patients with multiple myeloma (MM), but statistical confirmation of its superiority over other therapies, especially in the era of novel agents, is still lacking. Methods We reviewed the results of all 548 myeloma ASCTs performed in our institute over the past 18 years. Results More than one-half of the patients had access to novel agents before their transplantations. Although the age of the transplanted patients increased significantly over the years, treatment-related mortality (TRM) was remarkably low, especially in 1st-line transplanted patients (100-day TRM, 0.3%). The median overall survival (OS) of the entire cohort was 98.4 months. Patients transplanted within 12 months from the start of their therapy had significantly better responses than those having delayed ASCT (complete response rate, 58.1% vs 46.8%; P =.016) and significant post-ASCT progression-free survival (PFS) benefit (30.2 [26.1-34.3] mo vs 23.3 [16.8-29.8] mo; P =.036), but we found no significant overall survival difference. The results were similar in patients treated with or without novel agents before ASCT. During a period of time, interferon maintenance was our standard approach to post-ASCT maintenance. Our analysis showed not only a significant PFS advantage with interferon, but also a highly significant overall survival benefit (150.4 [105.1-195.8] mo vs 86.1 [72.5-99.7] mo; P =.003). Conclusions Our findings demonstrate that delayed ASCT can be feasible in selected patients.

AB - Background Autologous stem cell transplantation (ASCT) has become the mainstay of 1st-line treatment in younger patients with multiple myeloma (MM), but statistical confirmation of its superiority over other therapies, especially in the era of novel agents, is still lacking. Methods We reviewed the results of all 548 myeloma ASCTs performed in our institute over the past 18 years. Results More than one-half of the patients had access to novel agents before their transplantations. Although the age of the transplanted patients increased significantly over the years, treatment-related mortality (TRM) was remarkably low, especially in 1st-line transplanted patients (100-day TRM, 0.3%). The median overall survival (OS) of the entire cohort was 98.4 months. Patients transplanted within 12 months from the start of their therapy had significantly better responses than those having delayed ASCT (complete response rate, 58.1% vs 46.8%; P =.016) and significant post-ASCT progression-free survival (PFS) benefit (30.2 [26.1-34.3] mo vs 23.3 [16.8-29.8] mo; P =.036), but we found no significant overall survival difference. The results were similar in patients treated with or without novel agents before ASCT. During a period of time, interferon maintenance was our standard approach to post-ASCT maintenance. Our analysis showed not only a significant PFS advantage with interferon, but also a highly significant overall survival benefit (150.4 [105.1-195.8] mo vs 86.1 [72.5-99.7] mo; P =.003). Conclusions Our findings demonstrate that delayed ASCT can be feasible in selected patients.

UR - http://www.scopus.com/inward/record.url?scp=84959091289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959091289&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2015.12.031

DO - 10.1016/j.transproceed.2015.12.031

M3 - Article

C2 - 26915865

AN - SCOPUS:84959091289

VL - 48

SP - 177

EP - 184

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 1

ER -